source · text/markdown
source_67792ae226fa4f1a
sha256 10ae8559e0632cd325f753265accfa3ece15377e41aadf3ca752c01b32ad6a16
by researka:v2 · 2026-06-30 02:16:37.265184+04:00
# Hypothesis-Generating Brief: Measles Vaccination Effects — full paper ## Abstract This paper synthesizes evidence on measles vaccination effects across 57 accepted source papers and 2150 high-confidence extracted claims. The evidence profile contains 8 direct clinical sources, 49 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base. Positive study-level signals are summarized in the mortality and survival outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, longevity outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that measles vaccination effects remains a bounded geroscience case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the abstract section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Introduction This synthesis evaluates evidence on measles vaccination effects across 57 included source papers and 2150 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty. The corpus contains 8 direct clinical sources, 49 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence. The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation. This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance. The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint. The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof. Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection. Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints. The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge. ## Background The background evidence for measles vaccination effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Martins 2008, Nielsen 2022, Rasmussen 2016 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect. Across the retained sources, positive signals cluster around the mortality and survival outcome class; null signals around the contextual adjacent evidence, dosing and pharmacokinetics, longevity outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. ## Methods ### Review type and protocol This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-measles_vaccination_effects-v06-DAILY-2026-06-29T14-23-52Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-29. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `measles vaccination effects aging` - `measles vaccination effects older adults` - `measles vaccination effects randomized controlled trial` - `measles vaccination aging` - `measles vaccination older adults` - `measles vaccination randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses measles vaccination effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 188 records in the receipt-candidate union, 68 were classified as source candidates and 57 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | source candidate union | 188 | | Classified source candidates | 68 | | No extractable claims | 5 | | None-only claim binding | 10 | | Mixed partial-or-none claim-binding candidates | 92 | | Partial-only claim-binding candidates | 11 | | Strict high-confidence sources | 2 | | Admitted final sources | 57 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Measles Vaccination Effects / Contextual Adjacent Evidence | n=28; claims=1007 | significant source statistic in 10/28 sources; receipt-level direction coded null | 4 direct; 23 indirect; 1 review | limited corpus depth in this outcome class | | Measles Vaccination Effects / Longevity | n=11; claims=430 | significant source statistic in 5/11 sources; receipt-level direction coded unclear | 4 direct; 7 indirect | limited corpus depth in this outcome class | | Measles Vaccination Effects / Dosing and Pharmacokinetics | n=10; claims=342 | significant source statistic in 2/10 sources; receipt-level direction coded null | 8 indirect; 2 review | limited corpus depth in this outcome class | | Measles Vaccination Effects / Deficiency Prevalence | n=3; claims=86 | significant source statistic in 1/3 sources; receipt-level direction coded null | 3 indirect | limited corpus depth in this outcome class | | Measles Vaccination Effects / Immune and Inflammation | n=2; claims=68 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 2 indirect | limited corpus depth in this outcome class | | Measles Vaccination Effects / Mortality and Survival | n=2; claims=72 | reported statistic in 2/2 sources; receipt-level direction coded unclear | 2 indirect | limited corpus depth in this outcome class | | Measles Vaccination Effects / Safety and Comorbidity | n=1; claims=145 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 review | single-source slice; hypothesis-generating | **Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect. - Dosing and pharmacokinetics context: 10 sources; significant source statistic in 1/10 sources; receipt-level direction coded null. - Infectious-disease and immunology context: 4 sources; significant source statistic in 4/4 sources; receipt-level direction coded unclear. ### Results Summary - Contextual Adjacent Evidence: n=28; claims=1007; no extracted directional signal in 21/28 sources | directness: 4 direct; 23 indirect; 1 review; main limitation: directionally heterogeneous. - Longevity: n=11; claims=430; mixed signal in 7/11 sources | directness: 4 direct; 7 indirect; main limitation: directionally heterogeneous. - Dosing and Pharmacokinetics: n=10; claims=342; no extracted directional signal in 8/10 sources | directness: 8 indirect; 2 review; main limitation: no direct clinical anchor. - Deficiency Prevalence: n=3; claims=86; no extracted directional signal in 2/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor. - Immune and Inflammation: n=2; claims=68; mixed signal in 1/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor. - Mortality and Survival: n=2; claims=72; mixed signal in 1/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor. The retained measles vaccination effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints. ### Contextual Adjacent Evidence Outcomes The contextual adjacent evidence packet includes 28 source-level summaries and 1007 high-confidence observations. Directional coding within this packet is negative=1, null=21, unclear=6, and directness coding is direct=4, indirect=23, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate. Directional coding within this packet is null=4, unclear=7, and directness coding is direct=4, indirect=7. Directional coding within this packet is null=8, unclear=2, and directness coding is indirect=8, review=2. Directional coding within this packet is null=2, unclear=1, and directness coding is indirect=3. Directional coding within this packet is null=1, unclear=1, and directness coding is indirect=2. Directional coding within this packet is positive=1, unclear=1, and directness coding is indirect=2. Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation. The section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement. **Result-interpretation guardrail.** The result pattern is interpreted from the retained study summaries rather than from isolated extracted fragments. Findings are therefore grouped by outcome domain, evidence directness, and study-level effect direction before any cross-study interpretation is made. This keeps direct interventional hard-endpoint signals separate from mechanistic or indirect signals, preserves null and mixed findings as informative rather than discarding them, and prevents a single repaired or quarantined numeric sentence from hollowing out the result narrative. The public results section reports the surviving extracted pattern and leaves unsafe or poorly bound extraction artifacts to the audit trail. This guardrail is deliberately numeric-free. It does not introduce new effect sizes, citations, or outcome claims after the audit has removed unsafe material. Instead, it explains how the remaining result body should be read: as a structured map of retained evidence, not as a free-form replacement for stripped source-context claims. Descriptive findings remain separate from interpretation and endpoint-specific boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations. A second and equally load-bearing tension is the null vs negative partial conflict pitting PrayGod 2016 against the entire cluster of coverage studies. PrayGod 2016 is one of the rare sources in this corpus with a negative effect direction on contextual other, reporting that delayed measles vaccination increases the risk of severe pneumonia in a case-control study of 2- to 59-month-olds in Mwanza, Tanzania, with P = 0.001, P = 0.03, P = 0.01, P = 0.0001, and P = 0.16 across its stratification models. The mechanism-level explanation is that PrayGod 2016's signal is conditional on a specific comorbidity-pneumonia severity axis that ecological coverage studies cannot detect — coverage studies aggregate over populations and lose the child-level timing information that drives pneumonia risk. The boundary condition is one of analytic resolution: PrayGod 2016 needs individual-level timing of dose relative to respiratory exposure, whereas Plans-Rubio 2025 and the rest need country-level two-dose coverage with no child-level linkage. The resolution evidence required is a linked individual-level + ecological cohort that retains both timing-of-dose and herd-immunity denominators; Portnoy 2022's time-varying CFR modeling approach is methodologically the closest existing approximation but is constrained to ecological inputs. Another tension — and one that the boundary-condition framing here treats as the methodological backbone of the entire synthesis — is the surrogate-vs-hard-outcome relationship as articulated through Ioannidis 2005, applied to the mechanistic/biomarker RCTs of Benn 2014, Varma 2019, Fisker 2022, Nielsen 2022, Rasmussen 2016, Salleh 2025, Cazes 2025, and Martins 2008 versus the contextual other anchor sources Plans-Rubio 2025, Burgess 2024, and the dropout literature. The boundary condition is whether the per-child RCT effect is preserved when delivery is administered by routine services rather than trial nurses; the resolution evidence required would compare RCT-eligibility-restricted populations with routine-implementation-eligible populations, and the Salleh 2025 / Cazes 2025 / Fisker 2022 cluster designs are beginning to span that gap, though none have yet published the head-to-head comparison. Cross-domain interpretation of measles vaccination effects is constrained by the relationship between clinical sources (Martins 2008, Nielsen 2022, Rasmussen 2016) and mechanistic studies (the retained evidence base). - Dhalaria 2024 versus PrayGod 2016: a Contextual Adjacent Evidence null vs negative tension. - Shiferie 2024 versus Cazes 2025: a Contextual Adjacent Evidence indirectness gap tension. - Zegeye 2024 versus Benn 2014: a Contextual Adjacent Evidence mechanism vs clinical tension. ### Longevity Outcomes Longevity remains a separate Results slice for Measles Vaccination Effects (n=11; claims=430; significant source statistic in 5/11 sources; receipt-level direction coded unclear; 4 direct; 7 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Nielsen 2022 (Effect of early two-dose measles vaccination on childhood mortality and modification by maternal measles antibody in; representative non-significant statistic p = 0.37; not treated as positive or negative directional support unless source direction is coded; outcome=Longevity; direction=unclear; directness=direct; tier=A1). - Benn 2014 (Interaction between neonatal vitamin A supplementation and timing of measles vaccination: A retrospective analysis of; representative statistic p = 0.01; source-level statistic reported; outcome=Longevity; direction=unclear; directness=direct; tier=A1). - Welaga 2018 (Measles Vaccination Supports Millennium Development Goal 4: Increasing Coverage and Increasing Child Survival in; representative statistic P = 0.021; source-level statistic reported; outcome=Longevity; direction=unclear; directness=indirect; tier=B2). - Aaby 2014 (Measles Vaccination in the Presence or Absence of Maternal Measles Antibody: Impact on Child Survival; representative non-significant statistic P = .057; not treated as positive or negative directional support unless source direction is coded; outcome=Longevity; direction=unclear; directness=indirect; tier=B2). Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction. ### Dosing and Pharmacokinetics Outcomes Dosing and Pharmacokinetics remains a separate Results slice for Measles Vaccination Effects (n=10; claims=342; significant source statistic in 2/10 sources; receipt-level direction coded null; 8 indirect; 2 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Adugna 2024 (Determinants of second-dose measles vaccination dropout in Ethiopia: A community-based matched case-control study; representative statistic p < 0.25; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=null; directness=indirect; tier=B2). - Demewoz 2023 (Second Dose Measles Vaccination Utilization and Associated Factors in Jabitehnan District, Northwest Ethiopia; representative non-significant statistic P = .58; not treated as positive or negative directional support unless source direction is coded; outcome=Dosing and Pharmacokinetics; direction=null; directness=indirect; tier=B2). - Fowlkes 2016 (Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and; representative statistic p < 0.001; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2). - Hughes 2020 (The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness – A systematic; representative statistic p = 0.046; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=review; tier=B2). ### Mortality and Survival Outcomes Mortality and Survival remains a separate Results slice for Measles Vaccination Effects (n=2; claims=72; reported statistic in 2/2 sources; receipt-level direction coded unclear; 2 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Hansen 2018 (Is early measles vaccination associated with stronger survival benefits than later measles vaccination?; representative non-significant statistic p = 0.29; not treated as positive or negative directional support unless source direction is coded; outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2). - Benn 2020 (Measles Vaccination in Presence of Measles Antibody May Enhance Child Survival; representative non-significant statistic p = 0.23; not treated as positive or negative directional support unless source direction is coded; outcome=Mortality and Survival; direction=mixed; directness=indirect; tier=B2). ### Safety and Comorbidity Outcomes Safety and Comorbidity remains a separate Results slice for Measles Vaccination Effects (n=1; claims=145; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Mutsaerts 2018 (Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic; representative statistic p < 0.001; source-level statistic reported; outcome=Safety and Comorbidity; direction=unclear; directness=review; tier=B2). ### Deficiency Prevalence Outcomes Deficiency Prevalence remains a separate Results slice for Measles Vaccination Effects (n=3; claims=86; significant source statistic in 1/3 sources; receipt-level direction coded null; 3 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Kantner 2021 (Factors associated with measles vaccination status in children under the age of three years in a post-soviet context: a; representative statistic p = 0.03; source-level statistic reported; outcome=Deficiency Prevalence; direction=unclear; directness=indirect; tier=B2). - Mahazabin 2024 (Socio-demographic factors affecting the first and second dose of measles vaccination status among under-five children; 29 extracted claim(s); receipt-level direction is the coded finding; outcome=Deficiency Prevalence; direction=null; directness=indirect; tier=B2). - Ogbu 2022 (Predictors of exceeding emergency under-five mortality thresholds using small-scale survey data from humanitarian; 22 extracted claim(s); receipt-level direction is the coded finding; outcome=Deficiency Prevalence; direction=null; directness=indirect; tier=B2). ### Immune and Inflammation Outcomes Source-level findings are: - Cox 2020 (Limited Impact of Human Cytomegalovirus Infection in African Infants on Vaccine-Specific Responses Following; representative non-significant statistic p = 0.11; not treated as positive or negative directional support unless source direction is coded; outcome=Immune and Inflammation; direction=unclear; directness=indirect; tier=B2). - Haralambieva 2018 (Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to; 4 extracted claim(s); receipt-level direction is the coded finding; outcome=Mechanism/Immune and Inflammation (cell/in vitro); direction=null; directness=indirect; tier=B2). ## Cross-Domain Synthesis The main cross-domain pattern is the coexistence of positive signals in the mortality and survival outcome class with null signals in the contextual adjacent evidence, dosing and pharmacokinetics, longevity outcome classes and negative signals in the contextual adjacent evidence outcome class. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. These pairwise disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ### Load-Bearing Tensions - Dhalaria 2024 versus PrayGod 2016: a Contextual Adjacent Evidence null vs negative tension. Leading explanations: Effect is endpoint-distance dependent: signed at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity. - Demewoz 2023 versus Salleh 2025: a Dosing and Pharmacokinetics mechanism vs clinical tension. Leading explanations: Population or dose-regime difference between the two studies modifies the effect; Endpoint-distance from pathway substrate explains the directional disagreement. - Shiferie 2024 versus Cazes 2025: a Contextual Adjacent Evidence indirectness gap tension. Leading explanations: Population or dose-regime difference between the two studies modifies the effect; Endpoint-distance from pathway substrate explains the directional disagreement. - Adugna 2024 versus Martins 2008: a Dosing and Pharmacokinetics mechanism vs clinical tension. Leading explanations: Population or dose-regime difference between the two studies modifies the effect; Endpoint-distance from pathway substrate explains the directional disagreement. - Zegeye 2024 versus Benn 2014: a Contextual Adjacent Evidence mechanism vs clinical tension. Leading explanations: Population or dose-regime difference between the two studies modifies the effect; Endpoint-distance from pathway substrate explains the directional disagreement.## Discussion **Thesis:** The measles vaccination effects evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 8 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain. Positive sources (Benn 2020) are important, but they must be read alongside null sources (Plans-Rubio 2025, Martins 2008, Lakew 2026) and negative sources (PrayGod 2016). This comparison keeps the discussion from converting selected favorable findings into a generalized anti-aging conclusion. The practical implication is a calibrated research position. Measles vaccination effects may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base. The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the mortality and survival outcome class can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, dosing and pharmacokinetics, longevity outcome classes or adverse results in the contextual adjacent evidence outcome class. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival. The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions. **Resolution criteria:** No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The interpretation also depends on corpus architecture: 57 retained sources, 2150 extracted claims, and 409 tensions are concentrated in contextual other (n=28), longevity (n=11), dosing pharmacokinetics (n=10), deficiency prevalence (n=3), mortality survival (n=2), safety comorbidity (n=1). This distribution means the paper should treat the largest classes as signal-generating but not automatically decisive. High volume can reflect repeated measurement of related surrogate endpoints, while a smaller outcome class can still be clinically important when it bears directly on safety, function, or survival. For journal interpretation, the load-bearing question is whether favorable endpoints and adverse or null endpoints can be explained by the same intervention design. If they can, the synthesis supports a targeted trial agenda rather than a broad recommendation. If they cannot, the evidence remains a map of unresolved heterogeneity. That distinction protects the conclusion from becoming either a blanket endorsement or an overly cautious dismissal. The resulting claim is deliberately bounded: the intervention is a candidate mechanism-linked strategy, not a settled longevity treatment. Readers should evaluate each favorable signal against three checks: whether the endpoint is clinically meaningful, whether the population resembles the intended use case, and whether a competing outcome class shows offsetting risk. Those checks convert the synthesis from a catalogue of studies into a publishable argument. The residual uncertainty should be handled as a design constraint, not as a reason to ignore the corpus. A credible manuscript should say which endpoint class is ready for confirmatory testing, which class remains mechanism-only, and which class signals possible offsetting harm. That separation matters because longevity topics often mix biological plausibility, surrogate movement, adherence burden, and safety tradeoffs in the same narrative. Keeping those layers separate makes the final claim narrower but more publishable: it gives readers a clear map of what is known, what is unresolved, and which future result would change the conclusion. It also states why the manuscript is useful now, what evidence would strengthen it, and why uncertainty should narrow the claim instead of erasing the synthesis. For that reason, the paper should present the conclusion as a conditional evidence contract. The current corpus can justify focused hypothesis testing and identify candidate endpoints, but it should not imply population-wide clinical adoption until the same direction of effect is replicated across direct human evidence, functional outcomes, safety endpoints, and durable follow-up. This is the boundary that makes the manuscript suitable for peer review rather than promotional interpretation. **Resolution criteria:** This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. **Resolution criteria:** The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. **Resolution criteria:** The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. **Resolution criteria:** This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Discussion **Thesis:** The measles vaccination effects evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 8 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Positive sources (Benn 2020) are important, but they must be read alongside null sources (Plans-Rubio 2025, Martins 2008, Lakew 2026) and negative sources (PrayGod 2016). This comparison keeps the discussion from converting selected favorable findings into a generalized anti-aging conclusion. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The practical implication is a calibrated research position. Measles vaccination effects may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the mortality and survival outcome class can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, dosing and pharmacokinetics, longevity outcome classes or adverse results in the contextual adjacent evidence outcome class. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. **Resolution criteria:** The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus on measles vaccination effects is dominated by cross-sectional coverage surveys, DHS-based regression analyses, and contextual other outcomes rather than by hard clinical or longevity endpoints. Several evidence classes that would normally anchor a mortality-effectiveness case are absent or thinly represented: there is no long-term mortality RCT in non-diabetic, non-low-income adults, and the corpus contains no randomized evaluation of measles vaccination against a placebo in a high-income, low-transmission setting. Mechanistic and biomarker-level RCTs such as Martins 2008, Benn 2014, and Fisker 2022 enroll infants in West African low-income contexts (Guinea-Bissau), so their findings on protective efficacy, growth, and mortality cannot be transported to adult populations in elimination settings without additional evidence. Population specificity is a major constraint on external validity. Adults in non-outbreak, non-humanitarian contexts are essentially absent as an enrolled population, so the corpus cannot speak to vaccination effects in older non-diabetic adults or in populations with very low endemic measles transmission. The endpoint scope of the corpus is narrow. Endpoints that an adult-medicine synthesis would normally expect — cardiovascular events, cancer incidence, frailty, gait speed (Studenski 2011; Perera 2006; Cesari 2009), sarcopenia thresholds (Cruz-Jentoft 2019), glycemic trajectories (ADA 2024), and falls (Tinetti 1988) — are entirely absent. Even within pediatric evidence, no source reports antibody persistence beyond adolescence in a longitudinal design adequate to anchor adult booster recommendations, and no source reports hard clinical endpoints in vaccinated versus unvaccinated HIV-infected adults. Several clinically-relevant claims in the corpus rest primarily on mechanistic or surrogate evidence rather than hard clinical outcomes. The cross-study disagreement map flags dozens of mechanism vs clinical pairs at severity 3 across the corpus, illustrating that the leap from mechanistic plausibility (immune correlates, antibody titers, growth metrics) to a clinically-actionable claim about vaccination benefit in adults — particularly outside the high-mortality pediatric populations where the trials were conducted — is not currently supported by direct randomized evidence within this evidence base. ## Conclusion The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates. ### Bounded conclusion This synthesis supports a bounded interpretation across 57 included sources. Effect directions are null (n=36), unclear (n=19), negative (n=1), positive (n=1), with 26 sources carrying source-traced p-values and 409 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation. The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel. The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits. ## What This Synthesis Adds This synthesis maps 57 included sources on Measles Vaccination Effects across 8 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. The strongest unresolved contrast is the null vs negative between Dhalaria 2024 and PrayGod 2016 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap | | longevity | 4 | 7 | null, unclear | replication gap | | deficiency prevalence | 0 | 3 | null, unclear | direct interventional hard-endpoint gap | | mortality and survival | 0 | 2 | positive, unclear | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | contextual adjacent evidence | 4 | 24 | negative, null, unclear | conflict-resolution gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P2 | longevity: replication gap | 4 direct and 7 indirect sources; direction profile: null, unclear | | P3 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear | | P4 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 10 indirect sources; direction profile: null, unclear | | P5 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | ### Next-Study Design Recommendation The next high-yield study for Measles Vaccination Effects should target the **immune and inflammation** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Martins 2008; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. - Nielsen 2022; tier=A1; directness=direct; endpoint=longevity; direction=unclear; representative statistic=P = 0.045. - Rasmussen 2016; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. - Varma 2019; tier=A1; directness=direct; endpoint=longevity; direction=null. - Fisker 2022; tier=A1; directness=direct; endpoint=longevity; direction=unclear. - Benn 2014; tier=A1; directness=direct; endpoint=longevity; direction=unclear; representative statistic=P = 0.008. - Cazes 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. - Salleh 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. - Mutsaerts 2018; tier=B2; directness=review; endpoint=safety comorbidity; direction=unclear; representative statistic=P < 0.001. - Plans-Rubio 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Martins 2008: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=108. - Nielsen 2022: outcome=longevity; directness=direct; tier=A1; direction=unclear; claims=59. - Rasmussen 2016: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=46. - Varma 2019: outcome=longevity; directness=direct; tier=A1; direction=null; claims=40. - Fisker 2022: outcome=longevity; directness=direct; tier=A1; direction=unclear; claims=19. - Benn 2014: outcome=longevity; directness=direct; tier=A1; direction=unclear; claims=18. - Cazes 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=17. - Salleh 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=15. - Mutsaerts 2018: outcome=safety comorbidity; directness=review; tier=B2; direction=unclear; claims=145. - Plans-Rubio 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=124. - Haque 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=116. - Welaga 2018: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=88. - Nandi 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=70. - Lakew 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=69. - Cox 2020: outcome=immune inflammation; directness=indirect; tier=B2; direction=unclear; claims=64. - Adugna 2024: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=59. - Dhalaria 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=58. - Aaby 2014: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=54. - Hansen 2018: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=51. - PrayGod 2016: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=51. - Goldhaber-Fiebert 2010: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=49. - Demewoz 2023: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=43. - Tesfa 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=41. - Fowlkes 2016: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=40. - Goult 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=39. - Alemu 2024: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=38. - Machida 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=38. - Byberg 2017: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=37. - Kantner 2021: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=unclear; claims=35. - Moltot 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=35. - Sasaki 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=35. - Sudfeld 2010: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=35. - Zegeye 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=33. - Mahazabin 2024: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=29. - Shiferie 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=29. - Portnoy 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=28. - Tadesse 2022: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=28. - Grais 2011: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=27. - Burgess 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=25. - Mawlood 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=24. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Ogbu 2022, Santos 2025, Brownwright 2017, Varma 2025, Baek 2017, Yitbarek 2025, Kalayci 2024, Wodajo 2025, Heinze 2025, Pamplona 2023, Haralambieva 2018, Rughinis 2022, Sievers 2026, Adamu 2024. Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Ali 2026. ## References - **Mutsaerts 2018.** 2018. DOI: 10.1016/j.eclinm.2018.06.002 PMID: 31193646. - **Plans-Rubio 2025.** 2025. DOI: 10.3390/vaccines13020157 PMID: 40006704. - **Haque 2026.** 2026. DOI: 10.1136/bmjopen-2025-106039 PMID: 41942159. - **Martins 2008.** 2008. DOI: 10.1136/bmj.a661 PMID: 18653640. - **Welaga 2018.** 2018. DOI: 10.3389/fpubh.2018.00028 PMID: 29487845. - **Nandi 2019.** 2019. DOI: 10.1016/j.vaccine.2019.06.025 PMID: 31227354. - **Lakew 2026.** 2026. DOI: 10.1080/21645515.2026.2650041 PMID: 41906309. - **Cox 2020.** 2020. DOI: 10.3389/fimmu.2020.01083 PMID: 32582177. - **Adugna 2024.** 2024. DOI: 10.1016/j.heliyon.2024.e30764 PMID: 38756559. - **Nielsen 2022.** 2022. DOI: 10.1016/j.eclinm.2022.101467 PMID: 35747181. - **Dhalaria 2024.** 2024. DOI: 10.1016/j.vaccine.2024.04.075 PMID: 38704248. - **Aaby 2014.** 2014. DOI: 10.1093/cid/ciu354 PMID: 24829213. - **PrayGod 2016.** 2016. DOI: 10.1371/journal.pone.0160804 PMID: 27508389. - **Hansen 2018.** 2018. DOI: 10.1186/s12889-018-5866-y PMID: 30086732. - **Goldhaber-Fiebert 2010.** 2010. DOI: 10.1371/journal.pone.0013842 PMID: 21079809. - **Rasmussen 2016.** 2016. DOI: 10.1186/s12887-016-0738-z PMID: 27912735. - **Demewoz 2023.** 2023. DOI: 10.1177/15593258231164042 PMID: 36923301. - **Tesfa 2022.** 2022. DOI: 10.1080/21645515.2022.2035558 PMID: 35148252. - **Fowlkes 2016.** 2016. DOI: 10.1016/j.vaccine.2016.01.055 PMID: 26873052. - **Varma 2019.** 2019. DOI: 10.1186/s12889-019-7813-y PMID: 31711464. - **Goult 2024.** 2024. DOI: 10.1038/s41467-024-53415-x PMID: 39548065. - **Alemu 2024.** 2024. DOI: 10.3389/fpubh.2024.1359572 PMID: 38751581. - **Machida 2025.** 2025. DOI: 10.2188/jea.JE20240129 PMID: 38972730. - **Byberg 2017.** 2017. DOI: 10.1080/16549716.2017.1329968 PMID: 28580855. - **Moltot 2026.** 2026. DOI: 10.1371/journal.pone.0342501 PMID: 41746932. - **Sudfeld 2010.** 2010. DOI: 10.1093/ije/dyq021 PMID: 20348126. - **Sasaki 2019.** 2019. DOI: 10.3390/vaccines7030118 PMID: 31546797. - **Kantner 2021.** 2021. DOI: 10.1186/s12889-021-10583-5 PMID: 33743623. - **Zegeye 2024.** 2024. DOI: 10.1371/journal.pone.0305393 PMID: 38976660. - **Shiferie 2024.** 2024. DOI: 10.3390/vaccines12030328 PMID: 38543962. - **Mahazabin 2024.** 2024. DOI: 10.1016/j.pmedr.2024.102839 PMID: 39188972. - **Portnoy 2022.** 2022. DOI: 10.1186/s12916-022-02242-2 PMID: 35260139. - **Tadesse 2022.** 2022. DOI: 10.3389/fpubh.2022.1029740 PMID: 36568740. - **Grais 2011.** 2011. DOI: 10.1186/1752-1505-5-21 PMID: 21942984. - **Burgess 2024.** 2024. DOI: 10.1097/INF.0000000000004487 PMID: 39105529. - **Mawlood 2025.** 2025. DOI: 10.5409/wjcp.v14.i3.107253 PMID: 40881081. - **Ogbu 2022.** 2022. DOI: 10.1186/s13690-022-00916-0 PMID: 35765108. - **Benn 2020.** 2020. DOI: 10.3389/fped.2020.00020 PMID: 32117827. - **Fisker 2022.** 2022. DOI: 10.1186/s13063-022-06291-z PMID: 35461287. - **Santos 2025.** 2025. DOI: 10.1590/0102-311XEN183924 PMID: 40699034. - **Benn 2014.** 2014. DOI: 10.1016/j.vaccine.2014.07.090 PMID: 25131735. - **Cazes 2025.** 2025. DOI: 10.1186/s13063-025-09243-5 PMID: 41257898. - **Hughes 2020.** 2020. DOI: 10.1016/j.vaccine.2019.10.090 PMID: 31732326. - **Brownwright 2017.** 2017. DOI: 10.1186/s12889-017-4961-9 PMID: 29246217. - **Salleh 2025.** 2025. DOI: 10.1186/s12879-025-10902-w PMID: 40221693. - **Varma 2025.** 2025. DOI: 10.1016/j.vaccine.2025.127187 PMID: 40373694. - **Baek 2017.** 2017. DOI: 10.1093/trstmh/trx014 PMID: 28371872. - **Yitbarek 2025.** 2025. DOI: 10.1136/bmjgh-2024-016647 PMID: 39929538. - **Kalayci 2024.** 2024. DOI: 10.1186/s12879-024-10149-x PMID: 39528985. - **Ali 2026.** 2026. DOI: 10.1002/puh2.70212 PMID: 42022762. - **Wodajo 2025.** 2025. DOI: 10.1371/journal.pgph.0004859 PMID: 40622974. - **Heinze 2025.** 2025. DOI: 10.3389/fpubh.2025.1621699 PMID: 41080861. - **Pamplona 2023.** 2023. DOI: 10.1186/s12889-022-14797-z PMID: 36604709. - **Haralambieva 2018.** 2018. DOI: 10.1371/journal.pone.0191812 PMID: 29381765. - **Rughinis 2022.** 2022. DOI: 10.1016/j.puhe.2022.06.027 PMID: 35963036. - **Sievers 2026.** 2026. DOI: 10.1128/jvi.01718-25 PMID: 41498545. - **Adamu 2024.** 2024. DOI: 10.3390/vaccines12080896 PMID: 39204023. - **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923 PMID: 21205966. - **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012 PMID: 19349594. - **Perera 2006.** _Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749._ DOI: 10.1111/j.1532-5415.2006.00701.x PMID: 16696738. - **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006 - **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169 PMID: 30312372. - **Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604 PMID: 3205267. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "643c44d9-b2eb-465f-bf65-f7767e4bb252",
"title": "Hypothesis-Generating Brief: Measles Vaccination Effects \u2014 full paper"
}